Walleye Capital
IMVT icon

Walleye Capital’s Immunovant IMVT Stock Holding History

Walleye Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,600
Closed -$219K – 4662
2025
Q4 		$219K Buy
+8,600
New +$192K ﹤0.01% 3498
2024
Q2 		– Sell
-7,300
Closed -$236K – 5783
2024
Q1 		$236K Sell
7,300
-5,500
-43% -$201K ﹤0.01% 3861
2023
Q4 		$539K Buy
12,800
+12,700
+12,700% +$467K ﹤0.01% 2894
2023
Q3 		$3.84K Buy
+100
New +$2.26K ﹤0.01% 4634

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Walleye Capital's IMVT Position: Q1 2026 in Review

Walleye Capital increased its Immunovant (IMVT) stake by 273,000% in Q1 2026, buying an estimated $70.7K and bringing the position to 2,731 shares worth $67.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3810.

Walleye Capital first reported a position in IMVT in Q1 2021 and has held it in 11 quarters since. The position peaked at $9.48M in Q4 2022. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Walleye Capital held 2,731 shares of Immunovant worth $67.8K as of Q1 2026.
  • Walleye Capital bought 2,730 Immunovant shares in Q1 2026, an estimated $70.7K.
  • Immunovant made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3810 holding.
  • Walleye Capital first reported a position in Immunovant in Q1 2021 and has held it in 11 quarters since.
  • Walleye Capital's Immunovant position peaked at $9.48M in Q4 2022.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.